Abstracts tagged "interstitial lung disease"

Abstract Number: 0453 • ACR Convergence 2025
Safety of DMARDs in Rheumatoid Arthritis: A Nationwide Study of ILD Risk and Outcomes in RA-ILD
kyung-Ann Lee¹, Bora Lee², Hyun-Sook Kim³ and Se Hee Kim⁴, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Chosun University, GwangJu, Republic of Korea, ³Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ⁴Kyung Hee University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a potentially life-threatening extra-articular manifestation of RA. The comparative safety of disease-modifying antirheumatic drugs (DMARDs) in RA…
Abstract Number: 2265 • ACR Convergence 2025
Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
Ana Serrano-Combarro¹, Belén Atienza-mateo², Adrian Martin-Gutierrez³, Marta López-Maraver⁴, Libe Ibarrola⁵, Ivette Casafont-Solé⁶, Jesús Loarce⁷, Juan María Blanco-Madrigal⁸, Santos Castañeda⁹, Rafaela Ortega-Castro¹⁰, Natalia Mena Vázquez¹¹, Nuria Vegas Revenga¹², Lucia C. Domínguez-Casas¹³, Cilia Peralta-Ginés¹⁴, Carlos Fernández Díaz¹⁵, Javier Loricera¹⁶ and Ricardo Blanco¹⁷, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ⁴Hospital Universitario Araba, Vitoria, Spain, ⁵Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁷Ramón y Cajal University Hospital, Madrid, Spain, ⁸Rheumatology. Hospital Universitario Araba., Vitoria, Pais Vasco, Spain, ⁹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹¹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ¹²Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹³Hospital Universitario San Agustin, Aviles, Spain, Aviles, ¹⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁵H.U. Santa Lucia, Murcia, Spain, ¹⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
Abstract Number: 2047 • ACR Convergence 2025
Trends in Lung Transplant Listing Outcomes in Connective Tissue Disease associated Interstitial Lung Disease (CTD-ILD) Across Two Decades
Sambhawana Bhandari¹, Derek E. Byers¹ and Deepali Sen², ¹Washington University in St. Louis School of Medicine, St. Louis, ²Washington University in St Louis, Chesterfield, MO
Background/Purpose: Lung transplantation represents a potential life-extending therapy for patients with advanced CTD-ILD. This study aims to characterize lung transplant listing outcomes among CTD-ILD patients…
Abstract Number: 1820 • ACR Convergence 2025
Cytokine profiling in refractory systemic juvenile idiopathic arthritis reveals distinct signatures for macrophage activation syndrome and lung disease.
Taskin Sabit¹, Minyi Yu², Joy Baker¹, Sanjeev Dhakal³, Sam Chiang⁴, Scott Canna⁵, Randy Cron⁶, Lauren Henderson⁷, Karen Onel⁸, Mona Riskalla⁹, Tiphanie Vogel¹⁰, Pui Lee¹¹, Grant Schulert² and Alexei Grom², ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children hospital, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnnati, OH, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Boston Children's Hospital, Watertown, MA, ⁸HSS, New York, NY, ⁹University of Minnesota Masonic Children's Hospital, Minneapolis, MN, ¹⁰Baylor College of Medicine, Houston, TX, ¹¹Boston Children's Hospital, Newton, MA
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is a severe inflammatory disorder that affects the joints as well as other organ systems, with complications including Macrophage…
Abstract Number: 1574 • ACR Convergence 2025
A rise in serum KL-6 levels predicts subsequent progressive pulmonary fibrosis in patients with systemic sclerosis-associated interstitial lung disease
Keina Yomono¹, Suiyuan Huang², Dinesh Khanna² and Masataka Kuwana³, ¹Nippon Medical School, Bunkyo-ku, Tokyo, Japan, ²University of Michigan, Ann Arbor, MI, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Given the high variable clinical course of…
Abstract Number: 1219 • ACR Convergence 2025
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Vasiliki Syrmou¹, Ioannis Alexiou², Christos Liaskos³, Eleni Patrikiou³, THEODORA SIMOPOULOU⁴, Christina Katsiari⁵ and Dimitrios Bogdanos⁶, ¹University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, ²University General Hospital of Larisa, Larissa, Greece, ³University of Thessaly, Faculty of Medicine, Larisa, Greece, ⁴University Hospital of Larissa, Greece, Larissa, Greece, ⁵University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁶Professor, Larissa, Greece
Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
Abstract Number: 1002 • ACR Convergence 2025
ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
Xiao Zhang¹, linmang Qin² and Yixuan Li¹, ¹The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China (People's Republic), ²Sun Yat-sen University, gaungzhou, Guangdong, China (People's Republic)
Background/Purpose: The rising incidence of connective tissue disease-associated interstitial lung disease (CTD-ILD) significantly worsens patient prognosis. While its pathogenesis remains unclear, immune-inflammatory dysregulation—particularly enhanced immune…
Abstract Number: 0435 • ACR Convergence 2025
Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study
Ahmad Alomari¹, Reem Elmusa², Nikita Shah³, Miguel Rodriguez⁴ and Diala Alawneh⁵, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/ HCA - North florida hospital, Gainesville, FL, ³UCF/HCA Florida North Florida Hospital, Gainesville, FL, ⁴SIMED Rheumatology, Gainesville, FL, ⁵University of Florida, Gainesville, FL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
Abstract Number: 2262 • ACR Convergence 2025
Assessment of small airway disease in rheumatoid arthritis
Stéphane HILLIQUIN¹, Huy-Thong HUA², Hà Pham-Ngoc², Frédérique Aubourg², Nhât-Nam Lê-Dông², Sven Günther³, Nicolas ROCHE⁴, Jérôme AVOUAC⁵, Yannick Allanore⁶ and Anh-Tuan Dinh-Xuan², ¹Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, ²Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ³Unité exploration fonctionnelle respiratoire, Georges-Pompidou Hospital, APHP, PARIS, France, ⁴Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁵Rheumatology department, Cochin hospital, Paris, France, ⁶Université Paris Cité, Paris, France
Background/Purpose: The risk of interstitial lung disease is well established in Rheumatoid Arthritis (RA). Less is known about the airway involvement which has been estimated…
Abstract Number: 2031 • ACR Convergence 2025
Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
Genna Braverman¹, Kerri Aronson², Charlene Thomas² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell, New York, NY, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Interstitial lung disease (ILD) is common and important feature of systemic autoimmune rheumatic diseases (SARD). Rheumatologists and pulmonologists are central to the care of…
Abstract Number: 1778 • ACR Convergence 2025
Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
Verónica Pulito Cueto¹, Joao Carlos Batista-Liz¹, Rebeca Nieto-Nieto², Clara Vaquera-Illescas², Diego San Emeterio-Villar², Daniel Vicente-Mínguez², María Sebastián Mora-Gil², Belén Atienza-mateo³, Ana Serrano-Combarro⁴, David Iturbe-Fernández⁵, Victor M. Mora-Cuesta⁵, Carolina Aguirre-Portilla⁴, Jose M Cifrián⁵, Ricardo Blanco⁴ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ⁴Immunopathology Group, IDIVAL and Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the leading cause of mortality in patients with connective tissue diseases (CTDs) [1]. The onset of CTD-ILD…
Abstract Number: 1567 • ACR Convergence 2025
Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease
Enrico De Lorenzis¹, Rosa D'Abronzo², Pier Giacomo Cerasuolo³, Lucio Calandriello⁴, Gabriella Alonzi³, Giuseppe Cicchetti², gerlando Natalello³, Bruno Iovene⁵, Lucia Lanzo³, Francesco Varone⁶, Giacomo Sgalla⁷, Luca Richeldi⁸, anna Rita Larici⁴, Maria Antonietta D'Agostino³ and Silvia Laura Bosello⁹, ¹Catholic University of the Sacred Heart, Roma, Rome, Italy, ²Division of Radiology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, ³Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Radiology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶Division of Respiratory Medicine - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁸Division of Respiratory Medicine - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, ⁹Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is a major complication in systemic sclerosis (SSc) patients, associated with substantial morbidity and mortality. Functional, imaging, and clinical measures…
Abstract Number: 1217 • ACR Convergence 2025
Validation and clincial use of anti-MDA5 test – LIA versus ELISA
TING-YUAN LAN¹, pei-Hsinq lai², Tai-Ju Lee³, Ting-Wei Chang⁴, Kuan-Yen Lin⁵, Shao-Yu Pai⁶ and Ko-Jen Li⁷, ¹National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ²Taipei City Hospital, Taichung, Taiwan, ³National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ⁵National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan (Republic of China), ⁶National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁷National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Although immunoprecipitation (IP) remains the gold standard for detecting myositis autoantibodies, it is technically demanding and not widely available. Line immunoassay (LIA) has become…
Abstract Number: 0973 • ACR Convergence 2025
Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
Takuya Kotani¹, Takayasu Suzuka², Shogo Matsuda³ and Tohru Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ²Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ³Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan
Background/Purpose: S100 proteins are involved in the inflammatory responses of autoimmune diseases. We previously showed that S100 proteins regulate macrophage function via CD68. Based on…
Abstract Number: 0430 • ACR Convergence 2025
Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
fatih ŞAhiner¹, Mine Nokay², funda erbasan², Veli Yazisiz³ and Ender terzioglu², ¹Akdeniz University, Antalya, ²Akdeniz University, Antalya, Turkey, ³Akdeniz University, Faculty of Medicine, Antalya, Turkey
Background/Purpose: RA-ILD is significant determinants of morbidity and mortality. This study aims to evaluate the demographic and serological characteristics of RA-ILD patients and investigate the…

« Previous Page
1
…
5
6
7
8
9
…
47
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].